Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azithromycin + amlodipine is a combination of two pharmaceutical drugs, each with distinct mechanisms and indications. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 23S rRNA of the bacterial 50S ribosomal subunit, thereby blocking the transpeptidation/translocation step and assembly of the ribosome. This action results in broad-spectrum antibacterial activity and is used primarily for treating various bacterial infections[1][6]. Amlodipine is a dihydropyridine calcium channel blocker that acts as a peripheral arterial vasodilator by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle cells, leading to reduced peripheral vascular resistance and blood pressure. It is mainly indicated for hypertension and angina[4]. The combination does not represent a fixed-dose product but may be co-prescribed in clinical practice when both an antibiotic (azithromycin) and antihypertensive/antianginal therapy (amlodipine) are needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + amlodipine.